Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets March 18, 2025
Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated March 18, 2025
SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients March 18, 2025
FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC March 18, 2025
iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors March 18, 2025
Johnson & Johnson to not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 March 18, 2025
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for HNSCC March 18, 2025
BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113 March 18, 2025
ImmunoPrecise Antibodies and a Global Biotechnology Company Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics March 18, 2025
Head and Neck Cancer Registration Study Protocol Clears FDA Review; in Talks with Potential Partners Interested in Commercialization of Multikine March 18, 2025
Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia March 18, 2025
JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression March 18, 2025
SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced March 18, 2025
